ACOG
Alpha Cognition Inc.
NASDAQ · Financial Services · Financial - Conglomerates · CA
$8.61
+1.29%Oct 13, 2026, 12:30 UTC
The United States Patent and Trademark Office published Alpha Cognition’s patent application for a process to prepare benzgalantamine and its salts.
Source:Oct 1, 2026, 12:30 UTC
Alpha Cognition Inc. announced initial results from the CONVERGE real-world evidence evaluation of ZUNVEYL (benzgalantamine) use in long-term care, focusing on 180-day titration and concomitant medication patterns.
Source:Sep 10, 2026, 10:00 UTC
Saudi Minister Abdullah Alswaha met with Cognition AI Co-Founder and CEO Scott Wu to discuss expanding use of autonomous software engineering solutions and deploying Devin and software agents through HUMAIN's computing capabilities.
Source:Sep 9, 2026, 22:00 UTC
Alpha Cognition Inc. granted inducement stock options to purchase 25,000 shares of common stock to a new non-executive employee on September 8, 2026, under its 2026 Inducement Grant Plan.
Source:Aug 13, 2026, 22:04 UTC
Alpha Cognition reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer's treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter.
Jul 29, 2026, 12:30 UTC
Alpha Cognition Inc. received a European patent from the European Patent Office covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for treating mild-to-moderate Alzheimer's disease.
Source:Jul 9, 2026, 02:15 UTC
Cognition launches SWE-1.7, a new AI model trained from Kimi K2.7, available at 1,000 tokens per second.
Source:Jun 23, 2026, 13:00 UTC
Alpha Cognition Inc. elected Dr. Robert Wills as Chairman of the Board.
Source: